博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300294 博雅生物

交易中 12-25 10:43:54

{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":31.04,"timestamp":1735094634000,"preClose":30.98,"halted":0,"volume":2654741,"delay":0,"floatShares":504000000,"shares":504000000,"eps":0.3691,"marketStatus":"交易中","marketStatusCode":2,"change":0.06,"latestTime":"12-25 10:43:54","open":31.08,"high":31.38,"low":30.93,"amount":82843900,"amplitude":0.0145,"askPrice":31.05,"askSize":1,"bidPrice":31.04,"bidSize":148,"shortable":0,"etf":0,"ttmEps":0.3691,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1735097400000},"adr":0,"adjPreClose":30.98,"symbolType":"stock","openAndCloseTimeList":[[1735090200000,1735097400000],[1735102800000,1735110000000]],"highLimit":34.08,"lowLimit":27.88,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"pbRate":2.06,"roa":"--","roe":"5.55%","epsLYR":0.47,"committee":0.197952,"marketValue":15652000000,"floatMarketCap":15652000000,"peRate":84.09645,"changeRate":0.0019,"turnoverRate":0.0053,"status":0},"requestUrl":"/m/hq/s/300294/wiki","defaultTab":"wiki","newsList":[{"id":"2492161903","title":"华润医药附属华润医药控股增持华润博雅生物股份比例达到1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492161903","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492161903?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:06","pubTimestamp":1734566760,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　华润医药（03320）公布，于2024年11月8日至2024年12月18日期间，公司全资附属公司华润医药控股透过深圳证券交易所交易系统的集中竞价交易累计收购华润博雅生物额外504.24万股股份，占华润博雅生物股本总额的1.00%。\n　　截至本公告日期及于上述增持股份后，公司透过华润医药控股间接持有华润博雅生物总股本约30.28%及总股本约41.59%表决权。华润博雅生物作为该公司附属公司入账。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-19/doc-inczxzya0287560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03320","BK0239","BK0197","BK1191","300294","BK0046","BK1570"],"gpt_icon":0},{"id":"2492139414","title":"华润医药(03320.HK)累计增持华润博雅生物1%股本","url":"https://stock-news.laohu8.com/highlight/detail?id=2492139414","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492139414?lang=zh_cn&edition=full","pubTime":"2024-12-19 01:22","pubTimestamp":1734542520,"startTime":"0","endTime":"0","summary":"华润医药(03320.HK) 公布，11月8日至本月18日期间，透过深交所系统的集中竞价交易累计增持华润博雅生物504.24万股，占其总股本1%。增持后，公司共计持有华润博雅生物总股本41.59%表决权。公司拟自11月8日起六个月内，进一步增持华润博雅生物总股本不超过1.2%。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-18 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240827115743024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240827115743024_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405070/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03320","BK1570","BK0239","300294","BK1191","BK0197","BK0046"],"gpt_icon":0},{"id":"2492018124","title":"华润医药(03320)附属华润医药控股增持华润博雅生物股份比例达到1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492018124","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492018124?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:36","pubTimestamp":1734532603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)公布，于2024年11月8日至2024年12月18日期间，公司全资附属公司华润医药控股透过深圳证券交易所交易系统的集中竞价交易累计收购华润博雅生物额外504.24万股股份，占华润博雅生物股本总额的1.00%。截至本公告日期及于上述增持股份后，公司透过华润医药控股间接持有华润博雅生物总股本约30.28%及总股本约41.59%表决权。华润博雅生物作为该公司附属公司入账。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1570","BK0046","03320","BK0197","BK0239","300294","BK1191"],"gpt_icon":0},{"id":"2492078749","title":"12月18日博雅生物发布公告，其股东增持504.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492078749","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492078749?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:01","pubTimestamp":1734523292,"startTime":"0","endTime":"0","summary":"证券之星消息，12月18日博雅生物发布公告《博雅生物:公司关于控股股东增持公司股份达到1%暨后续增持计划的公告》，其股东华润医药控股有限公司于2024年11月8日至2024年12月18日间合计增持504.24万股，占公司目前总股本的1.0%，变动期间该股股价下跌5.6%，截止12月18日收盘报30.53元。股东增减持详情见下表：根据博雅生物2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800035394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"gpt_icon":0},{"id":"2492013899","title":"博雅生物(300294.SZ)控股股东华润医药控股累计增持1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2492013899","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492013899?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:17","pubTimestamp":1734520671,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)公告，公司控股股东华润医药控股有限公司(简称华润医药控股)于2024年11月8日-12月18日通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份504.24万股，占公司总股本的比例为1.0000%。此外，华润医药控股自2024年11月8日起6个月内拟通过证券法规允许的方式增持公司股份，总增持股份数量(含本次已增持)不低于总股本的1%(即504.24万股)，且不超过总股本的1.2%(即605.09万股)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1570","BK0197","BK0239","BK0046","03320","BK1191","300294"],"gpt_icon":0},{"id":"2492901763","title":"博雅生物最新公告：控股股东增持公司股份达到1% 后续拟继续增持不超过总股本的0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492901763","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492901763?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:10","pubTimestamp":1734520242,"startTime":"0","endTime":"0","summary":"博雅生物公告，控股股东华润医药控股有限公司于2024年11月8日至12月18日，通过集中竞价交易方式累计增持公司股份504.24万股，占公司总股本的1.0000%。后续拟继续增持不超过总股本的0.2%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800033324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"gpt_icon":0},{"id":"2491664746","title":"博雅生物(300294.SZ)：卡前列素氨丁三醇注射液拟中标全国药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2491664746","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491664746?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:59","pubTimestamp":1734346757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)公告，公司全资子公司南京新百药业有限公司(简称新百药业)参加了国家组织药品联合采购办公室组织的第十批全国药品集中采购的投标工作。新百药业的产品卡前列素氨丁三醇注射液拟中标本次集中采购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2491665067","title":"博雅生物最新公告：全资子公司新百药业产品卡前列素氨丁三醇注射液拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491665067","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491665067?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:40","pubTimestamp":1734345644,"startTime":"0","endTime":"0","summary":"博雅生物公告，全资子公司新百药业参加了联采办组织的第十批全国药品集中采购的投标工作，其产品卡前列素氨丁三醇注射液拟中标本次集中采购。本次拟中选产品的采购周期自中选结果执行之日起至2027年12月31日。新百药业后续签订采购协议并实施，将扩大相关产品的销售规模，提高市场占有率，提升品牌影响力。但上述产品的采购协议签订等后续事项及对公司未来业绩影响尚具有不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600025704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"gpt_icon":0},{"id":"2491665312","title":"博雅生物：全资子公司产品拟中标第十批全国集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2491665312","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491665312?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:36","pubTimestamp":1734345370,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0197","600682","BK0070","BK0093","BK0113","BK0209","BK0042","BK0183","BK0196","BK0060","BK0114","BK0046","300294","BK0239"],"gpt_icon":0},{"id":"2490355128","title":"博雅生物(300294)12月10日股东户数2.45万户，较上期减少1.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490355128","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490355128?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:05","pubTimestamp":1733907920,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2024年12月10日公司股东户数为2.45万户，较11月29日减少463.0户，减幅为1.85%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至12月10日，生物制品行业平均股东户数为3.38万户。从股价来看，2024年11月29日至2024年12月10日，博雅生物区间涨幅为0.29%，在此期间股东户数减少463.0户，减幅为1.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100028033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2488995470","title":"博雅生物(300294)11月29日股东户数2.5万户，较上期减少5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488995470","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488995470?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:07","pubTimestamp":1733216862,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2024年11月29日公司股东户数为2.5万户，较11月8日减少1446.0户，减幅为5.47%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至11月29日，生物制品行业平均股东户数为3.38万户。从股价来看，2024年11月8日至2024年11月29日，博雅生物区间跌幅为1.51%，在此期间股东户数减少1446.0户，减幅为5.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120300029694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"gpt_icon":0},{"id":"2488951928","title":"博雅生物：公司产品与干细胞无关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2488951928","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488951928?lang=zh_cn&edition=full","pubTime":"2024-12-02 16:15","pubTimestamp":1733127329,"startTime":"0","endTime":"0","summary":"中国财富通12月2日 - 博雅生物（300294）在互动平台上表示，公司主要从事血液制品的研发、生产和销售，血液制品是指从健康人血浆中通过分离纯化等方式，提取出来的血浆蛋白制品。公司产品与干细胞无关联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=z55e6bHt%2Fj0%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","300294","BK0197","BK0239"],"gpt_icon":0},{"id":"2486516743","title":"博雅生物（300294）7830.86万股限售股将于11月25日解禁，占总股本15.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486516743","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486516743?lang=zh_cn&edition=full","pubTime":"2024-11-25 08:02","pubTimestamp":1732492946,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，博雅生物于11月25日将有7830.86万股限售股份解禁，为公司定向增发机构配售股份，占公司总股本15.53%。博雅生物主营业务：公司业务以血液制品为主,生化药、化学药为辅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500001211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300294"],"gpt_icon":0},{"id":"2486748729","title":"188.64亿元市值限售股今日解禁，九丰能源、中远海发、博雅生物解禁市值居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2486748729","media":"界面","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486748729?lang=zh_cn&edition=full","pubTime":"2024-11-25 07:57","pubTimestamp":1732492667,"startTime":"0","endTime":"0","summary":"Wind数据显示，周一（11月25日），共有18家公司限售股解禁，合计解禁量为20.25亿股，按最新收盘价计算，合计解禁市值为188.64亿元。从解禁量来看，5家公司解禁股数超千万股。中远海发、九丰能源、江苏新能解禁量居前，解禁股数分别为14.48亿股、3.6亿股、8807.59万股。从解禁市值来看，5家公司解禁股数超亿元。九丰能源、中远海发、博雅生物解禁市值居前，解禁市值分别为98.01亿元、37.65亿元、24.61亿元。从解禁股数占总股本比例来看，4家公司解禁比例超10%。九丰能源、博雅生物、海力风电解禁比例居前，解禁比例分别为55.89%、15.53%、12.27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125075747a252dba1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125075747a252dba1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0252","BK0197","BK0102","BK0239","02866","BK0188","BK0010","BK0011","BK0006","BK0012","BK0183","605090","601866","BK0020","300294","BK0028","BK0270","BK0046"],"gpt_icon":0},{"id":"2484165458","title":"11月20日博雅生物涨5.84%，南方医药保健灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165458","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484165458?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:12","pubTimestamp":1732090347,"startTime":"0","endTime":"0","summary":"证券之星消息，11月20日博雅生物涨5.84%，收盘报32.28元，换手率4.02%，成交量17.13万手，成交额5.46亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为南方医药保健灵活配置混合A。南方医药保健灵活配置混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000026786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"gpt_icon":0},{"id":"2484165466","title":"博雅生物涨5.84%，国金证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165466","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484165466?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:12","pubTimestamp":1732090342,"startTime":"0","endTime":"0","summary":"今日博雅生物涨5.84%，收盘报32.28元。2024年8月24日，国金证券研究员袁维发布了对博雅生物的研报《血制品实现稳定增长，静待浆源拓展落地》，该研报对博雅生物给出“买入”评级。研报中预计公司2024-2026年分别实现归母净利润5.54、6.15、6.74亿元。维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为东方财富证券的何玮。博雅生物个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000026783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2484301913","title":"博雅生物(300294.SZ)：7830.86万股限售股于11月25日可上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2484301913","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484301913?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:51","pubTimestamp":1732009878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)公告，公司向特定对象华润医药控股有限公司发行的股份本次解除限售后实际可上市流通的数量为7830.86万股，占公司总股本的15.5298%。可上市流通日：2024年11月25日(星期一)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0197","BK0239","300294"],"gpt_icon":0},{"id":"2483407846","title":"博雅生物(300294)11月8日股东户数2.64万户，较上期增加2.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483407846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483407846?lang=zh_cn&edition=full","pubTime":"2024-11-13 17:03","pubTimestamp":1731488627,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2024年11月8日公司股东户数为2.64万户，较10月31日增加726.0户，增幅为2.82%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至11月8日，生物制品行业平均股东户数为3.38万户。从股价来看，2024年10月31日至2024年11月8日，博雅生物区间涨幅为2.36%，在此期间股东户数增加726.0户，增幅为2.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300028860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"gpt_icon":0},{"id":"2481667370","title":"博雅生物最新公告：完成收购绿十字香港控股有限公司100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2481667370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481667370?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:31","pubTimestamp":1730889084,"startTime":"0","endTime":"0","summary":"博雅生物公告，公司于2024年7月17日审议通过收购绿十字香港控股有限公司100%股权的议案，使用自有资金人民币18.2亿元协议受让该股权。2024年11月6日，公司收到绿十字（香港）发来的《关于完成股东名册变更登记的函》，获悉绿十字（香港）已完成股东名册的变更登记，股权交割程序已完成。上述股东名册变更完成后，公司持有绿十字（香港）100%的股权，并开始将其纳入合并报表范围。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600031636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"gpt_icon":0},{"id":"2481442673","title":"博雅生物：完成收购绿十字香港控股有限公司100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2481442673","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481442673?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:30","pubTimestamp":1730889047,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0197","BK0239","300294","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业园区惠泉路333号","stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0103},{"period":"6month","weight":-0.0538},{"period":"1year","weight":-0.049},{"period":"ytd","weight":-0.0668}],"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","perCapita":"20264股","boardName":"医药制造业","registeredCapital":"50424万元","compareEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":0.0387},{"period":"3month","weight":0.1717},{"period":"6month","weight":0.152},{"period":"1year","weight":0.1626},{"period":"ytd","weight":0.1407}],"survey":"　　华润博雅生物制药集团股份有限公司的主营业务以血液制品为主，集生化药、化学药、原料药为辅。公司的主要产品为血液制品业务、天安药业的糖尿病用药业务、新百药业的生化类用药业务、博雅欣和化学药业务、复大医药经销业务。公司是全国较早通过国家药品新版GMP认证的企业之一，公司生产线采用过程自动控制系统对生产过程进行控制，实现了全程CIP、SIP及关键参数的自动记录。公司严格按国家相关规定组织生产和质量控制，大大提高了产品安全性、质量可控性，产品质量指标高于国家标准。","serverTime":1735094645412,"listedPrice":25,"stockholders":"24883人(较上一季度增加1.45%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}